(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 9.61%
0.00% $ 1.100
Live Chart Being Loaded With Signals
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...
Stats | |
---|---|
Volumen de hoy | 38 137.00 |
Volumen promedio | 130 140 |
Capitalización de mercado | 41.94M |
EPS | $0 ( 2024-04-03 ) |
Próxima fecha de ganancias | ( $-0.510 ) 2024-05-09 |
Last Dividend | $0.0900 ( 2014-08-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.600 |
ATR14 | $0.0140 (1.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Yonehiro Grant | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Perez Edith A. | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Schatzman Randall C | Buy | 654 000 | Stock Option (Right to Buy) |
2024-03-04 | Quinn William P. | Buy | 235 000 | Stock Option (Right to Buy) |
2023-12-31 | Yonehiro Grant | Buy | 0 |
INSIDER POWER |
---|
72.99 |
Last 93 transactions |
Buy: 5 349 325 | Sell: 1 125 168 |
Volumen Correlación
Bolt Biotherapeutics, Correlación
10 Correlaciones Más Positivas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bolt Biotherapeutics, Correlación - Moneda/Commodity
Bolt Biotherapeutics, Finanzas
Annual | 2023 |
Ingresos: | $7.88M |
Beneficio Bruto: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2023 |
Ingresos: | $7.88M |
Beneficio Bruto: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2022 |
Ingresos: | $5.73M |
Beneficio Bruto: | $838 000 (14.63 %) |
EPS: | $-2.30 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.97 |
Financial Reports:
No articles found.
Bolt Biotherapeutics, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2012-03-06 |
Last Dividend | $0.0900 | 2014-08-29 |
Next Dividend | $0 | N/A |
Payout Date | 2014-10-02 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.830 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0.326 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.424 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.501 | 1.500 | -6.68 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.06 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.528 | 1.500 | 8.18 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 53.10 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.919 | -1.838 | [0 - 20] |
debtEquityRatioTTM | 0.179 | -1.500 | 9.28 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.577 | 1.000 | 3.72 | 3.72 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.67 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0493 | 0.800 | -3.00 | -2.40 | [0.5 - 2] |
Total Score | 0.326 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.616 | 1.000 | -0.163 | 0 | [1 - 100] |
returnOnEquityTTM | -0.501 | 2.50 | -4.29 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.613 | -1.838 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00459 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -8.83 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.76 |
Bolt Biotherapeutics,
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico